Telesis Bio’s New Financing and Governance Shake-Up
Company Announcements

Telesis Bio’s New Financing and Governance Shake-Up

The latest announcement is out from Telesis Bio (TBIO).

Telesis Bio Inc. has secured a $5.85 million loan through promissory notes with major stakeholders Novalis Lifesciences II and Northpond Ventures III, carrying a 12% annual interest rate and due by January 2026. In tandem with this borrowing, the company settled all previous debts under its agreements with MidCap Financial Trust and MidCap Funding IV, totaling $5,842,651.25. Additionally, the lenders have gained significant influence by agreeing to a side letter that stipulates the expansion of Telesis Bio’s Board to 13 directors and the appointment of five lender-nominated directors. This move consolidates the lenders’ strategic involvement in the company’s governance, reflective of their substantial ownership interest.

See more insights into TBIO stock on TipRanks’ Stock Analysis page.

Related Articles
TipRanks Auto-Generated NewsdeskTelesis Bio Inc. Faces Financial Challenges Amidst Revenue Decline
Christine BrownTBIO Earnings this Week: How Will it Perform?
TipRanks Auto-Generated NewsdeskTelesis Bio Announces Departure of Chief Legal Officer
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App